- Home
- VKTX
as 01-21-2025 4:00pm EST
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.7B | IPO Year: | 2015 |
| Target Price: | $106.75 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.92 - $99.41 | Next Earning Date: | 02-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Viking Therapeutics Inc. (VKTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mancini Marianna | VKTX | Chief Operating Officer | Jan 3 '25 | Sell | $43.00 | 54,215 | $2,317,599.12 | 374,134 | |
| ZANTE GREG | VKTX | Chief Financial Officer | Jan 3 '25 | Sell | $43.00 | 50,309 | $2,150,594.66 | 169,959 | |
| Lian Brian | VKTX | President & CEO | Jan 3 '25 | Sell | $43.00 | 194,490 | $8,313,601.16 | 2,385,570 | |
| MACARTNEY LAWSON | VKTX | Director | Nov 8 '24 | Sell | $68.67 | 2,000 | $137,333.40 | 47,965 | |
| ZANTE GREG | VKTX | Chief Financial Officer | Oct 28 '24 | Sell | $78.19 | 131,687 | $10,089,164.06 | 169,959 | |
| SINGLETON J MATTHEW | VKTX | Director | Oct 25 '24 | Sell | $79.50 | 16,000 | $1,272,000.00 | 9,500 | |
| Rouan Sarah Kathryn | VKTX | Director | Oct 25 '24 | Sell | $80.89 | 11,000 | $889,790.00 | 0 |
Latest Viking Therapeutics Inc. News
VKTX Breaking Stock News: Dive into VKTX Ticker-Specific Updates for Smart Investing
Quartz
a day ago
The race for the next Ozempic is on
Zacks
2 days ago
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Insider Monkey
2 days ago
Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week
Motley Fool
5 days ago
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
Insider Monkey
5 days ago
Why Viking Therapeutics (VKTX) Is the Biotech Stock with Biggest Upside Potential
Zacks
7 days ago
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
BioPharma Dive
8 days ago
JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning
Motley Fool
8 days ago
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Compare VKTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VKTX Viking Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.